Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment

Reuters11-06

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment

Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581062998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062998","market":"nz","top_or_hot":-1,"title":"Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989772840.SGD","symbol_name":"CPR Invest - Climate Action A2 Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1MJDGy:1","article_id":"2581062998","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062998","pubTimestamp":1762430536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0784383803.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A\" (USD) INC A","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","AZN.UK":"阿斯利康制药","NDAQ":"纳斯达克OMX交易所","BK4007":"制药","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","FBIO":"Fortress Biotech Inc.","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","ATXI":"Avenue Therapeutics, Inc.","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1153584641.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USDHDG) ACC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","LU1003076772.USD":"BGF EUROPEAN EQUITY INCOME \"A5G\" (USDHDG) INC","BK4585":"ETF&股票定投概念","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0784384876.USD":"Blackrock Global Multi-Asset Income A6 USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0784385840.USD":"Blackrock Global Multi-Asset Income A2 USD","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","03165":"华夏欧优股对冲","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","BK5011":"制药","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics获得AZD7325用于癫痫治疗的全球权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AXSM":0.9,"FBIO":0.9,"AZN.UK":0.9,"NDAQ":0.9,"ATXI":0.9},"content_text":"Axsome Therapeutics Acquires Global Rights to AZD7325 for Epilepsy Treatment\n    \n\n        Axsome Therapeutics has obtained exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of 100% equity interest in Baergic Bio, Inc., a subsidiary of Avenue Therapeutics. The deal includes commercial, development, and manufacturing rights to AZD7325, which has shown anti-convulsant effects in preclinical seizure models and demonstrated a favorable safety and tolerability profile in clinical studies involving over 700 patients. Baergic Bio shareholders will receive a $0.3 million upfront payment, with potential development, regulatory, and sales-based milestone payments, as well as tiered royalties on global net sales. AstraZeneca, the original licensor, will receive a cash upfront payment in the single digit millions, additional milestone payments, and tiered royalties. Axsome plans to advance AZD7325 into Phase 2 trial-enabling activities for epilepsy in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570134-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581062998","isCrawlerRequest":true}